



UNIVERSITY OF LEEDS

This is a repository copy of *Resection margin involvement after endoscopic excision of malignant colorectal polyps: definition of margin involvement and its impact upon tumour recurrence*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/197998/>

Version: Supplemental Material

Article:

Scott, N, Cairns, A, Prasad, P et al. (6 more authors) (2023) Resection margin involvement after endoscopic excision of malignant colorectal polyps: definition of margin involvement and its impact upon tumour recurrence. *Histopathology*, 83 (1). pp. 80-90. ISSN 0309-0167

<https://doi.org/10.1111/his.14903>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1. Relationship between Malignant Polyp Features, Loco-Regional Recurrence and Distant Metastasis in 159 patients with clinical follow-up.

Polyp Cancer Characteristic	No. of cases	Loco-Regional Recurrence	Distant Metastasis	Adverse Outcome	P value
Screen detected	50 (31.4%)	8 (16 %)	5 (10 %)	10 (20 %)	pNS
Symptomatic	109 (68.6 %)	12 (11 %)	3 (2.8 %)	12 (11 %)	
En-bloc excision	124 (78 %)	13 (10.5 %)	7 (5.6 %)	16 (12.9 %)	pNS
Piecemeal excision	35 (22 %)	6 (17.1 %)	1 (2.9 %)	7 (20 %)	
Paris type 1p	48	3 (6.3%)	2 (4.2%)	4 (8.3%)	pNS
Paris type 1sp	39	6 (15.4%)	3 (7.7%)	8 (20.5%)	
Paris type 1s	29	4 (13.8%)	1 (3.4%)	4 (13.8%)	
Paris type II	28	3 (10.7%)	2 (7.1%)	3 (10.7%)	
well differentiated	141 (88.7 %)	14 (9.9 %)	5 (3.5 %)	16 (11.3 %)	P<0.01
poorly differentiated	18 (11.3 %)	6 (33.3 %)	3 (16.7 %)	7 (38.9 %)	
LVI	37 (23.3 %)	6 (16.2 %)	3 (8.1 %)	7 (18.9 %)	pNS
No LVI	122 (76.7 %)	14 (11.5%)	5 (4.1 %)	16 (13.1 %)	
BVI	21 (13.2%)	4 (19 %)	2 (9.5 %)	4 (19 %)	pNS
No BVI	138 (86.8 %)	16 (11.6 %)	6 (4.3 %)	19 (13.8 %)	
Mucinous ca	12 (8.1 %)	4 (33.3 %)	2 (16.7 %)	4 (33.3 %)	pNS
Non-mucinous ca	137 (91.9 %)	15 (10.9 %)	6 (4.4 %)	18 (13.1 %)	
Margin 0 mm	34 (22.4 %)	11 (32.3 %)	3 (8.8 %)	12 (35.3 %)	P<0.01
Margin > 0 mm	118 (77.6 %)	7 (5.9 %)	4 (3.4 %)	9 (7.6 %)	
Margin 0-1 mm	87 (58.4 %)	15 (17.2 %)	5 (5.7 %)	16 (18.4 %)	P<0.05
Margin > 1mm	62 (41.6 %)	3 (4.8 %)	2 (3.2 %)	4 (6.5 %)	
Coagulation pos*	57 (38.3 %)	15 (26.3 %)	5 (8.8 %)	17 (29.8 %)	P<0.01
Coagulation neg**	92 (61.7 %)	3 (3.3 %)	2 (2.2%)	4 (4.3 %)	
Total	159	20 (12.6%)	8 (5%)	23 (14.5%)	

P values are for difference in Adverse Outcome.

* carcinoma within zone of coagulation artefact ** outside zone of coagulation artefact.